Related Experiment Video
Updated: Jan 16, 2026

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
Published on: May 18, 2020
Optimizing innovation in pharma: how organizational agility unlocks quality performance through employee engagement
Nicholas M Rosemarino1, Charles H Jones1, Catarina R Dolsten1
1Aktum Group LLC, New York, NY 10016, USA.
Abstract:
Pharmaceutical firms must balance innovation with rigorous quality standards. Drawing from Job Demands-Resources (JD-R) theory, we examined how organizational agility unlocks the benefits of an innovation-supportive climate. Using a two-wave methodological design from 250 employees in the USA, moderated mediation analyses demonstrated that innovation climate exerted indirect effects on quality performance through engagement, but only when organizational agility was high. These findings suggest that innovation climates alone are insufficient. Instead, organizational agility functions as the crucial organizational-level resource that channels creative energy into employee engagement and quality outcomes, a dynamic particularly salient in pharmaceutical settings.
More Related Videos
05:45Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
Published on: April 7, 2023
05:47Simulation of a Scaled Assembly Process with Collaboration of a Robotic Arm and Monitoring through a Vision System for Quality Control
Published on: August 29, 2025
Related Concept Videos
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Biopharmaceutics and Pharmacokinetics: Overview
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence